Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Show more

Location: 1111 Kane Concourse, Bay Harbor Islands, FL, 33154, United States | Website: https://www.avenuetx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

2.611M

52 Wk Range

$0.17 - $2.93

Previous Close

$0.86

Open

$0.62

Volume

1,896

Day Range

$0.60 - $0.86

Enterprise Value

-715.5K

Cash

3.326M

Avg Qtr Burn

-1.254M

Insider Ownership

18.41%

Institutional Own.

3.15%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IV Tramadol Details Pain, Post operative acute pain	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BAER-101 Details Anxiety Disorders, Epilepsy	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AJ201 Details Huntington's disease, Spinal and bulbar muscular atrophy , Spinocerebellar Ataxia, Kennedy's Disease	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.